Design Therapeutics Inc expected to post a loss of 41 cents a share - Earnings Preview

Design Therapeutics

31/10/2023 24:00

* Design Therapeutics Inc  DSGN.OQ   DSGN.O  is expected
to show
no change in quarterly revenue when it reports  results 
    * 
    * ​Refinitiv's mean analyst estimate for Design Therapeutics
Inc
is for a loss of 41 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Design
Therapeutics Inc is $6.5​, above​ its last closing price
of $2.04. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.39       -0.40      -0.36     Beat    9.4
 Mar. 31 2023  -0.36       -0.36      -0.35     Beat    2.6
 Dec. 31 2022  -0.38       -0.34      -0.31     Beat    9.9​
 Sep. 30 2022  -0.29       -0.29      -0.32     Missed  -11.1
 ​​Jun.        -0.25       -0.25      -0.27     Missed  -8
 30 2022                                                
 Mar. 31 2022  -0.22       -0.22      -0.24     Missed  -9.1​
 Dec. 31 2021  -0.25       -0.23      -0.20     Beat    11.8
 Sep. 30 2021  -0.14       -0.14      -0.21     Missed  -50
 This summary was machine generated October 31 at 00:00 GMT.  All
figures in US dollars  unless otherwise stated